关键词: 非感染性葡萄膜炎, 肿瘤坏死因子-α抑制剂, 阿达木单抗

Abstract: Non-infectious uveitis (NIU) is a group of immune-mediated diseases with complex etiology and difficult treatment. Tumor necrosis factor-α (TNF-α) is the key pro-inflammatory factor in NIU. Adalimumab is a fully humanized monoclonal antibody targeting TNF-α, specifically binding to TNF-α and therefore blocking its induced downstream processes. Application of adalimumab in NIU including uveitis caused by Behcet's disease, Vogt-Koyanagi-Harada syndrome, ankylosing spondylitis-related uveitis, and children's uveitis can effectively reduce inflammation, the dosage of glucocorticoid, and the recurrence rate. Its safety has also been initially confirmed. Adalimumab is a suitable option for second-line treatment of NIU and shows great potential in the treatment of NIU. (Int Rev Ophthalmol, 2022, 46:  336-340)

Key words: non-infectious uveitis, tumor necrosis factor -α inhibitors, adalimumab